Core Insights - Clearmind Medicine Inc. has received a Notice of Allowance for a patent related to its MEAI treatment for binge behavior, enhancing its intellectual property protection and portfolio [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] - The recent patent allowance strengthens the company's position in the psychedelic therapeutics space and supports the development of its MEAI program [2][3]